Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Achieving plasma HIV RNA below the level of detection in clinical practice

Achieving plasma HIV RNA below the level of detection in clinical practice Clinical trials have shown that highly active antiretroviral therapy (HAART) reduces plasma HIV RNA below the detection level in up to 90 per cent of patients. To assess the independent predictors that are associated with achieving undetectable plasma HIV RNA in the daily clinical practice, we carried out a retrospective study. Among 106 HIV‐infected patients treated with HAART, 63 (59 per cent) achieved undetectable plasma HIV RNA (less than 400 copies/ml) at their last visit. Adherence with HAART (greater than 80 per cent of prescribed dose) was self‐reported by 81 patients (76 per cent). Independent predictors of achieving undetectable plasma HIV RNA were: self‐reported adherence to therapy (Odds ratio (OR) 11.79, 95 per cent Confidence intervals (CI): 3.55‐33.17, p = 0.0001) and lack of previous antiretroviral therapy (OR: 3.12, 95 per cent CI: 1.09‐8.96, p = 0.03). The efficacy of antiretroviral therapy observed in the daily clinical practice was noticeably lower than that reported in clinical trials. Patient adherence with prescribed HAART and lack of previous antiretroviral therapy are important factors related to successful therapy in the real world. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Clinical Governance Emerald Publishing

Achieving plasma HIV RNA below the level of detection in clinical practice

Download PDF
5 pages

Loading next page...
 
/lp/emerald-publishing/achieving-plasma-hiv-rna-below-the-level-of-detection-in-clinical-T0TUE8thQS
Publisher
Emerald Publishing
Copyright
Copyright © 2000 MCB UP Ltd. All rights reserved.
ISSN
1466-4100
DOI
10.1108/14664100010343971
Publisher site
See Article on Publisher Site

Abstract

Clinical trials have shown that highly active antiretroviral therapy (HAART) reduces plasma HIV RNA below the detection level in up to 90 per cent of patients. To assess the independent predictors that are associated with achieving undetectable plasma HIV RNA in the daily clinical practice, we carried out a retrospective study. Among 106 HIV‐infected patients treated with HAART, 63 (59 per cent) achieved undetectable plasma HIV RNA (less than 400 copies/ml) at their last visit. Adherence with HAART (greater than 80 per cent of prescribed dose) was self‐reported by 81 patients (76 per cent). Independent predictors of achieving undetectable plasma HIV RNA were: self‐reported adherence to therapy (Odds ratio (OR) 11.79, 95 per cent Confidence intervals (CI): 3.55‐33.17, p = 0.0001) and lack of previous antiretroviral therapy (OR: 3.12, 95 per cent CI: 1.09‐8.96, p = 0.03). The efficacy of antiretroviral therapy observed in the daily clinical practice was noticeably lower than that reported in clinical trials. Patient adherence with prescribed HAART and lack of previous antiretroviral therapy are important factors related to successful therapy in the real world.

Journal

British Journal of Clinical Governance – Emerald Publishing

Published: Jun 1, 2000

Keywords: AIDS; Hospitals; Clinical guidelines

References

  • Predictors of long‐term response to protease inhibitor therapy in a cohort of HIV‐infected patients
    Casado, J.L; Pérez‐Elias, M.J; Antela, A; Sabido, R; Marti‐Belda, P; Dronda, F. et al
  • Phenotypic resistance testing significantly improves response to therapy: a randomized trial (VIRA 3001)
    Cohen, C; Hunt, S; Sension, M; Farthing, C; Conant, M; Jacobson, S. et al
  • HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy
    Deeks, S.G; Hecht, F.M; Swanson, M; Elbeik, T; Loftus, R; Cohen, P.T; Grant, R.M
  • Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
    Detels, R; Munoz, A; McFarlane, G; Kingsley, L.A; Margolick, J.B; Giorgi, J
  • Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial
    Durant, J; Clevenbergh, P; Halfon, P; Delgiudice, P; Porsin, S; Simonet, P
  • Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral antiretroviral therapy
    Gulick, R.M; Mellors, J.W; Havlir, D; Eron, J.J; Gonzalez, C; McMahon, D.
  • A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell count of 200 per cubic millimeter or less
    Hammer, S.M; Souires, K.E; Hughes, M.D; Grimes, J.M; Demeter, L.M; Currier, J.S
  • Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions
    Lucas, G.M; Chaisson, R.E; Moore, R.D
  • A preliminary study of ritonavir, an inhibitor of HIV‐1 protease, to treat HIV‐1 infection
    Markowitz, M; Saag, M; Powderly, W.G
  • Potential factors affecting adherence with HIV therapy
    Mehta, S; Moore, R.D; Graham, N.M.H
  • Acceptance and adherence with antiretroviral therapy among HIV‐infected women in a correctional facility
    Mostashari, F.M; Riley, E; Selwyn, P.A; Altice, F.L
  • Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out‐patient Study Investigators
    Palella, F.J. Jr; Delaney, K.M; Moorman, A.C; Loveless, M.O; Fuhrer, J; Satten, G.A
  • Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross‐sectional study in a municipal hospital clinic
    Samet, J.H; Libman, H; Steger, K.A; Dhawan, R.V; Chen, J; Shevitz, A.H.
  • Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance
    Singh, N; Squier, C; Sivek, C; Wagener, M; Hong Nguyen, M; Yu, V.L
  • Extrapolation of Data from Clinical Trials. Guide to Clinical Trials
    Spilker, B
  • Virological response to protease inhibitor therapy in an HIV clinic cohort
    Staszewski, S; Miller, V; Sabin, C; Carlebach, A; Berger, A.M; Weidmann, E
  • Human immunodeficiency virus I protease inhibitors in clinical practice: predictors of virological outcome
    Valdez, H; Lederman, M.M; Woolley, I.; Walker, C.J; Vernon, L.T; Hise, A; Gripshover, B.M